According to our (Global Info Research) latest study, the global Afamelanotide market size was valued at US$ 69.76 million in 2025 and is forecast to a readjusted size of US$ 116 million by 2032 with a CAGR of 7.6% during review period.
Afamelanotide is a synthetic peptide drug, an analog of alpha-melanocyte-stimulating hormone (α-MSH), used as a subcutaneous implant to prevent painful skin reactions from sun exposure in patients with the rare genetic disorder Erythropoietic Protoporphyria (EPP). It works by stimulating melanin (specifically eumelanin) production in the skin, which blocks light and reduces the severe pain, redness, and swelling caused by EPP. Administered as a small implant under the skin, it's released slowly over about two months.
Global production of afanotide is projected to reach 3,000 vials by 2025, with an average price of US$22,600 per vial. Gross profit margins typically remain at a high level of 70% to 85%.
Afamelanotide is a synthetic analog of melanocyte-stimulating hormone. Its upstream industry chain mainly consists of peptide raw materials and amino acid monomers, solid-phase synthesis resins and reagents, solvents, lyophilization excipients, sterile packaging materials, and bioanalytical testing services. The upstream focus lies in high-purity peptide synthesis and consistent quality control. Downstream demand is highly concentrated in rare disease and niche dermatology treatments, with its primary use in improving phototolerance for patients with erythropoietic protoporphyria. End users are mainly specialized hospitals, rare disease treatment centers, and reimbursement systems. Given the small and clearly defined patient population, downstream stakeholders prioritize clinical efficacy, safety, ease of administration, and long-term adherence. Payment is often supported by public insurance, special funds, or premium commercial insurance, resulting in relatively low price sensitivity but high requirements for clinical evidence. As real-world data accumulates, downstream applications are gradually expanding toward additional photosensitivity-related indications, while remaining focused on specialist channels and academic promotion.
In terms of industry trends, Afamelanotide products are moving toward indication expansion, optimized delivery methods, and stronger real-world evidence generation. Key growth drivers include supportive orphan drug policies, incentives for rare disease development, and increasing advocacy from patient organizations. Major constraints include a limited patient base that caps market size, high development and regulatory costs, complex manufacturing barriers, and strong dependence on a single core product.
This report is a detailed and comprehensive analysis for global Afamelanotide market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Afamelanotide market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Afamelanotide market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Afamelanotide market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Afamelanotide market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Afamelanotide
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Afamelanotide market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Clinuvel Pharmaceuticals, Evonik Industries, Hangzhou Go Top Peptide Biotech, Zhejiang Hengtengfu, Wepon, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Afamelanotide market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Subcutaneous Implants
Injectables
Transdermal Patches
Oral Preparations
Topical Preparations
Market segment by Chemical Structure
Α-MSH Analogs
Acetate Derivatives
Free Peptide Derivatives
Long-Acting Modified Derivatives
Market segment by Pharmacological Effects
MC1R Selective Agonists
Melanin Synthesis Stimulants
Anti-Inflammatory Agents
Neuroprotective Agents
Market segment by Application
Hematologic Disorders
Skin Pigmentary Disorders
Acute Diseases
Autoimmune Diseases
Neurodegenerative Diseases
Major players covered
Clinuvel Pharmaceuticals
Evonik Industries
Hangzhou Go Top Peptide Biotech
Zhejiang Hengtengfu
Wepon
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Afamelanotide product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Afamelanotide, with price, sales quantity, revenue, and global market share of Afamelanotide from 2021 to 2026.
Chapter 3, the Afamelanotide competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Afamelanotide breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Afamelanotide market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Afamelanotide.
Chapter 14 and 15, to describe Afamelanotide sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Afamelanotide. Industry analysis & Market Report on Afamelanotide is a syndicated market report, published as Global Afamelanotide Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Afamelanotide market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.